AiomNews Speciale Tumore del Seno e Biopsia Liquida N. 26

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy

Introduction: Activating ESR1 mutations are a major mechanism of resistance to aromatase inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer (mBC). International guidelines, including those from ASCO, NCCN, and ESMO, recommend liquid biopsy as the preferred approach for ESR1 mutation testing at progression on endocrine therapy, with digital PCR (dPCR) and next-generation sequencing (NGS) as the preferred analytical platforms. Although elacestrant was approved by the U.S. Food and Drug Administration … Continua a leggere

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization

My co-authors and I would like to thank Doctor Tjalma for his comments, which give us the opportunity to explain in depth the differences between certification and recommendations and how Eusoma proceeds with its documents. Here are our point by point replies to Doctor Tjalma’s statements. … Continua a leggere

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Background: In DESTINY-Breast06, trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) versus physician’s choice of chemotherapy (TPC) for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low/-ultralow metastatic breast cancer (mBC), without new safety signals. We report additional analyses exploring outcomes for patients with characteristics that affect prognosis… Continua a leggere

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Purpose: The WSG TP-II trial (ClinicalTrials.gov identifier: NCT03272477) was designed to compare the impact of 12 weeks of neoadjuvant trastuzumab + pertuzumab combined with endocrine therapy (ET) versus chemotherapy (once per week paclitaxel) on the pathologic complete response (pCR) rate and survival in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) … Continua a leggere

International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study

Background: The COVID-19 pandemic had an impact on cancer services globally. There is a crucial need to understand how the incidence and stage of major cancer types were affected internationally. We aimed to assess these metrics in seven countries within the International Cancer Benchmarking Partnership.
Methods: This population-based study used data on 2·6 million patients diagnosed with primary cancers of the colon, rectum, lung, prostate, female breast, ovary, and melanoma of the skin, between Jan 1, 2015, and Dec 31, 2020 … Continua a leggere